A WTW survey puts employer coverage at 53%, down from 57%. CNBC lays out what workers can turn to instead, from LillyDirect and NovoCare to reimbursement plans.
Recap by typeshit. Full story at CNBC.
Business Day says medicines endorsed by the WHO still aren't available to public sector patients. The drugs involved aren't named in the share.
A study of 288,907 insured people found other medical costs rose about 22 cents per drug dollar. Also covers Medicare's $245 Bridge price and employer cutbacks.
ASU's Justin Bina told the New York Post that people starting GLP-1 drugs become willing to pay more per pound for certain proteins, even as cattle stocks hit a 75-year low.
Zacks expects $10.1 billion from Mounjaro and $5.1 billion from Zepbound, and notes Lilly plans to seek retatrutide approval in early 2027.
Inc. reports on research into a fat-burning pathway that works differently from Ozempic, which acts on appetite.
A short social share on how the two semaglutide brands differ for diabetes and weight loss. Thin on detail, so tap through for the full comparison.
Loading…